Helus Pharma and TARA Mind Target Veteran Mental Health—Phase 3 Recruitment for HLP003 Ramps Up

Collaboration Seeks to Bridge Veteran Access to Mental Health Innovation

Helus Pharma™ (NASDAQ:HELP), a clinical-stage leader in novel serotonergic agonists (NSAs), has announced a new partnership with TARA Mind, a mental health care platform with long-standing ties to veteran support networks. This alliance is designed to accelerate recruitment for the HLP003 Phase 3 trial targeting major depressive disorder (MDD), specifically aiming to reach U.S. veteran communities disproportionately affected by mental health challenges.

Presidential Executive Order Spurs Broader Initiatives

This move closely follows the April 18, 2026 Executive Order from President Trump, focused on “Accelerating Medical Treatments for Serious Mental Illness.” The order calls for expanded clinical trial participation and greater access to innovative treatments—issues at the heart of this new collaboration. With clinical research showing breakthrough potential for NSAs in conditions like depression and PTSD, Helus Pharma looks to connect more veterans with evidence-based therapies previously out of reach.

Phase 3 PARADIGM Program Zeroes in on Veterans

The PARADIGM HLP003 program is at the forefront of Helus Pharma’s pipeline, having already achieved FDA Breakthrough Therapy Designation. By leveraging TARA Mind’s and Veterans Exploring Treatment Solutions’ (VETS) outreach, the program aims to recruit veterans for participation, improving representation in research and potentially offering earlier access to novel therapies.

Patient-Centric Strategy and Sector Implications

According to Helus Interim CEO Eric So, the partnership is about more than trial enrollment: “Veterans face significant mental health challenges, and expanding awareness and access to clinical research opportunities is an important step toward improving outcomes.” With the support of TARA Mind’s data-driven care platform and VETS’ community network, the goal is to not only accelerate trial recruitment but also foster long-term awareness and resource availability in the veteran space.

Implications for the Broader Mental Health Landscape

Industry observers see this as a blueprint for how innovative drug companies might partner with specialized organizations to address community-specific needs—particularly where standard care has fallen short. The executive order’s timing boosts both regulatory momentum and public awareness, as stakeholders in pharma and mental health rally around evidence-backed, scalable solutions.

Forward-Looking Statements Highlight Potential and Caution

While Helus Pharma’s clinical ambitions are bold, management tempers expectations, citing the inherent uncertainties of drug development and regulatory approval. The company acknowledges that outcomes hinge on ongoing trials, FDA review, and the evolving landscape of mental health policy. Investors and healthcare advocates alike are watching to see if partnerships like this can translate to improved care and broader acceptance of new therapeutics.

Key Takeaway: Veteran Recruitment Could Pave the Way for Future Mental Health Approaches

With federal backing and a focused approach, Helus Pharma’s partnership with TARA Mind may set new standards for trial engagement in underserved communities. For now, the collaboration stands as a notable effort to align innovative science with real-world outreach—particularly for veterans seeking hope against mental illness.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI